SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116229 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Nai-Jung Chiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung Univ…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Veterans General Hospital, National Health Research Institutes, National Science and Technology Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Therapeutic and Research Center of Pancreatic…
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, T…
- Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Hematology Oncology, E-Da Cancer…
- Division of Hematology-Oncology, Department of Internal Medicine, China Medical University Hospital and China Medical University, Taichung, Taiwan.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, Taiwan; Division of Clin…
- Division of Hematology-Oncology, Department of Internal Medicine, Linkou, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Förderung
- Taipei Veterans General Hospital
- National Health Research Institutes
- National Science and Technology Council
- Melissa Lee Cancer Foundation
Zitieren
APA
Chiang, N. J., Su, Y. Y., Ho, I. W., Bai, L. Y., Li, C. P., Chen, J. S., Hsiao, C. F., Tsou, H. H., Hsu, C., Chiu, T. J., Hsieh, Y. Y., Rau, K. M., Ho, C. L., Shan, Y. S., & Chen, L. T. (2026). SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116229
Vancouver
Chiang NJ, Su YY, Ho IW, Bai LY, Li CP, Chen JS, et al. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116229
BibTeX
@article{Chiang2026,
author = {Chiang, Nai-Jung and Su, Yung-Yeh and Ho, I-Wei and Bai, Li-Yuan and Li, Chung-Pin and Chen, Jen-Shi and Hsiao, Chin-Fu and Tsou, Hsiao-Hui and Hsu, Chiun and Chiu, Tai-Jan and Hsieh, Yao-Yu and Rau, Kun-Ming and Ho, Ching-Liang and Shan, Yan-Shen and Chen, Li-Tzong},
title = {SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116229}
}
EUVIMED